DLA PIPER LLP (US) for GENENTECH USA, INC.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislative and regulatory policies affecting biotechnology including: pharmaceutical development, approval reimbursement, and pricing; patient assistance and access programs; and benefit redesign. H.R. 5376, Build Back Better Act, drug pricing provisions. Labor/HHS/Education Appropriations for FY2023, provisions regarding pandemic response. CMS National Coverage Determination for Alzheimer's treatment. Potential pilot program combatting influenza.
Foreign entity interest: Roche Holdings, AG, interests are those of parent company.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES GREENWOOD | — |
| JAMIE ALEXEI GREGORIAN | — |
| ALEX PINSON New | Schedule C appointee, Dept. of Health and Human Services; Senior Legis. Asst. and Counsel (and other positions), Rep. Hal Rogers; Intern, Rep. Cory Gardner; Intern, Rep. Trey Gowdy |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.